

# COVIDIV - Collateral damage of the COVID-19 pandemic observed among patients receiving treatment with intravitreal (IVT) injections of antiangiogenic agents

Head :Mauget-Faÿsse Martine

Last update : 04/23/2021 | Version : 1 | ID : 73553

## General

### Identification

Detailed name	Collateral damage of the COVID-19 pandemic observed among patients receiving treatment with intravitreal (IVT) injections of antiangiogenic agents
Sign or acronym	COVIDIV

### General Aspects

Medical area	Ophthalmology
Study in connection with Covid-19	Yes
Pathology (details)	Exudative ARMD, diabetes, retinal vein occlusion (RVO), or other disorders causing macular oedema

### Scientific investigator(s) (Contact)

Name of the director	Mauget-Faÿsse
Surname	Martine
Address	Hôpital Fondation A. de Rothschild, PIC-CIC, 29 rue Manin 75019 PARIS
Phone	01 48 03 64 37
Organization	Foundation A. de Rothschild Hospital

### Collaborations

Participation in projects, networks and consortia	No
---	----

### Funding

#### Governance of the database

Sponsor(s) or organisation(s)	Foundation A. de Rothschild Hospital/Clinical
-------------------------------	---

responsible	Research Unit
Organisation status	Both
Presence of scientific or steering committees	No

### Additional contact

Name of the contact	VACHEY
Surname	Patrick
Address	Hôpital Fondation A. de Rothschild, PIC-CIC, 29 rue Manin 75019 PARIS
Phone	01 48 03 64 33
Email	pvachey@for.paris
Organization	Hôpital Fondation A. de Rothschild

Name of the contact	THEVENIN
Surname	Sophie
Address	Hôpital Fondation A. de Rothschild, PIC-CIC, 29 rue Manin 75019 PARIS
Phone	01 48 03 65 96
Email	sthevenin@for.paris
Organization	Hôpital Fondation A. de Rothschild

### Main features

#### Type of database

Type of database	Others
Specify	Questionnaire at inclusion + follow-up data taken from the medical records
Database recruitment is made on the basis of:	Medication(s) taken
Database recruitment is carried out as part of an interventional study	No
Additional information regarding	Patient information following their first visit after the

sample selection.	first lockdown on 11/05/2021: Patients contacted by telephone or informed during appointments.
-------------------	--

## Database objective

Main objective	Describe the changes in visual acuity among patients receiving treatment with repeat IVT injections of antiangiogenic agents during the COVID-19 epidemic, between September 2019 and May 2021
----------------	--

Inclusion criteria	Patient aged 18 years and over -Eye disorder requiring treatment with repeat IVT injections of antiangiogenic agents: Exudative ARMD, macular oedema associated with diabetes or secondary to retinal vein occlusion. -Initiation of treatment with repeat IVT injections before 01/10/2019
--------------------	---

## Population type

Age	Adulthood (19 to 24 years) Adulthood (25 to 44 years) Adulthood (45 to 64 years) Elderly (65 to 79 years) Great age (80 years and more)
-----	---

Population covered	Sick population
--------------------	-----------------

Pathology	H35 - Other retinal disorders
-----------	-------------------------------

Gender	Male Woman
--------	---------------

Geography area	National
----------------	----------

## Data collection

### Dates

Date of first collection (YYYY or MM/YYYY)	2020
--	------

### Size of the database

Size of the database (number of individuals)	[1000-10 000[ individuals
--	---------------------------

Details of the number of individuals	1,500 planned - actual number included: 233
--------------------------------------	---

## Data

Database activity	Current data collection
Type of data collected	Clinical data Declarative data
Clinical data (detail)	Direct physical measures
Details of collected clinical data	Treatment with IVT injections, outcome of the treated disorder
Declarative data (detail)	Phone interview
Details of collected declarative data	Questionnaire on visits during the lockdown
Presence of a biobank	No

## Procedures

Participant monitoring	Yes
Details on monitoring of participants	Follow-up with data in the medical records up to a year after resuming follow-up after 11/05/2021
Links to administrative sources	No

## Promotion and access

### Promotion

### Access